Johnson & Johnson Settles Baby Powder Lawsuit With Plaintiffs for $5.5 Billion

For the settlement to take effect, 95 percent of the plaintiffs must agree to it. The prerequisite is that leading plaintiff law firms at the national and state levels join the settlement. Johnson & Johnson plans to initially pay three billion dollars in 2027, with further payments to follow in 2028. Analysts had already forecast in 2025, however, that this number could rise to more than 90,000.

Wave of Lawsuits and Background

Because it provides no cap, payments could rise to seven billion dollars or more depending on the number of participating plaintiffs, said plaintiffs' attorney Chris Seeger. According to plaintiffs' attorney Seeger, this provides those affected with more money. In addition, payments would be accelerated so that all claims are settled within 18 months, rather than litigating them over more than a decade.

For more than three years, the pharmaceutical giant had tried in vain to handle the wave of lawsuits through the bankruptcy of a specially created subsidiary. However, this strategy failed in court. Critics had long accused Johnson & Johnson, as one of the most profitable companies in the world, of exploiting bankruptcy rules intended for insolvent companies in order to shield itself from the lawsuits. The settlement follows years of litigation and failed attempts by J&J to resolve the lawsuits through bankruptcy.

Mixed Trial Record and Individual Verdicts

Before these bankruptcy attempts, J&J's legal track record in the talc trials had been mixed: Alongside a billion-dollar verdict in favor of 22 women, the company had won some trials or achieved reductions in damages amounts on appeal. Just in October, a jury in the US state of California had ordered Johnson & Johnson to pay $966 million to the family of a deceased woman. It was the highest individual verdict in favor of a single plaintiff to date in this litigation. She had attributed her cancer to the lifelong use of the company's baby powder.

J&J attorney Erik Haas reiterated that the allegations were unfounded. The conglomerate now wants to finally end the long-running legal dispute. "Although we are confident that the company would ultimately have prevailed had the proceedings continued – as it already has in the overwhelming majority of cases tried to date – this settlement allows us to put this matter behind us and focus on our mission of developing medicines and medical technology that save lives," said Erik Haas, Vice President of Litigation at Johnson & Johnson.

Company's Position and Reactions

Plaintiffs accuse the manufacturer that its baby powder and other talc products were contaminated with asbestos and caused cancer. Johnson & Johnson has consistently rejected the allegations, stating repeatedly that talc does not cause cancer and that asbestos has never been present in the baby powder. has consistently denied the allegations and emphasized the safety of its products.

Just last week, a US federal judge had expressed doubts about whether the plaintiffs could prove that the talc was actually the cause of their cancer. This question is also at the center of the now-reached settlement, which according to Johnson & Johnson represents an "efficient resolution" of the wave of lawsuits. The proposed settlement represented an "efficient resolution" of the lawsuit wave, the company said.

J&J had already discontinued the sale of talc-based baby powder in the US in 2020 and replaced it with a cornstarch-based product. the sale of the talc-based powder was initially discontinued in 2020 in the US. In June, Johnson & Johnson had announced that it had set aside a total of $11 billion for the talc litigation. Funds are now available for the now-agreed settlement payment, which is significantly below the original provisions.

Financial Provisions and Market Reaction

Unlike the earlier bankruptcy plans, the settlement now reached does not cover future lawsuits. According to plaintiffs' attorney Seeger, this means more money is available for those affected – because no funds would need to be reserved for possible new proceedings, more capital flows into the ongoing cases.

With the settlement, a legal dispute that has burdened the US company for more than 15 years could be ended. After more than ten years of litigation over allegedly cancer-causing baby powder, Johnson & Johnson (J&J) is drawing a billion-dollar line under the matter. The stock rose by just under three percent in premarket US trading on Tuesday, which was interpreted on the market as a signal for greater legal certainty.

Outlook and Next Steps

Legal experts view the settlement as the most extensive out-of-court compromise to date in a mass lawsuit against a US consumer goods company. The structure with staggered payouts and a minimum participation of 95 percent of the plaintiffs is considered unusual and is intended to ensure that the remaining claims are actually settled.

The case had also occupied regulators and the political debate in the US for years. At the center was the question of how robust the scientific evidence is for a connection between talc contamination and cancer. While epidemiological studies have sometimes pointed to an increased risk of ovarian cancer, J&J had consistently submitted its own expert opinions denying such a connection.

With the settlement now announced, this scientific and legal dispute is shifting. While the company is not abandoning its position on the safety of its products, it is at the same time accepting the financial resources to end the litigation. Industry observers see this primarily as a hedge against further individual lawsuits and possible punitive damages claims.

According to the company, the first payments to plaintiffs are scheduled to begin in 2027. The prerequisite is that the required threshold of 95 percent approval is reached. Should this threshold be missed, J&J could, according to observers, be forced to re-enter into individual negotiations with thousands of remaining plaintiffs.

Overall, the settlement demonstrates the growing willingness of large corporations in the US to withdraw from lengthy mass lawsuits through billion-dollar settlements. For Johnson & Johnson, according to its own statements, the step means being able to focus more strongly on its core business of pharmaceuticals and medical technology in the future.